AMT Medical

Executive Summary

AMT Medical, a Dutch medical device company founded in 2003, is developing the Elana® Anastomotic System, a novel device designed to simplify the most complex step in coronary artery bypass graft (CABG) surgery. The system aims to enable reproducible, off-pump, and minimally invasive surgical approaches, including future robotic-assisted procedures. By standardizing the anastomosis process, AMT's technology has the potential to reduce operative time, improve patient outcomes, and expand access to minimally invasive cardiac surgery. The company is based in Maastricht and operates in the medical devices sector, targeting a significant unmet need in cardiovascular surgery. The Elana System addresses a critical bottleneck in CABG procedures, which are among the most common cardiac surgeries worldwide. Current manual anastomosis techniques are technically demanding and variable, limiting adoption of minimally invasive and off-pump approaches. AMT's device could unlock broader use of robotic-assisted CABG, currently constrained by the complexity of suturing. With an aging population and rising prevalence of coronary artery disease, the market opportunity is substantial. The company's progress toward regulatory approvals and clinical validation will be key value drivers in the near term.

Upcoming Catalysts (preview)

• Q3 2026CE Mark Approval for Elana System70% success
• Q4 2026FDA Investigational Device Exemption (IDE) Approval60% success
• H1 2027First Clinical Study Results (Pivotal Trial Data)50% success